We have discovered DEGA, a novel cDNA differentially expressed in human gastric adenocarcinomas. The DEGA gene product contains a signal peptide, five leucine-rich repeat motifs and a single IgG, and transmembrane domain, suggesting its residence on the plasma membrane. Transfection of 293 cells with a DEGA-GFP fusion construct confirmed its cell surface localization. Although the cytosolic portion of the DEGA gene product does not contain known protein domains, approximately one-fifth of these residues are either a serine or a threonine, suggesting that DEGA may play a role in signal transduction. BLAST searches revealed DEGA to be an exact match to AMIGO-2, a recently identified, but functionally uncharacterized protein related to AMIGO, a leucine-rich repeat containing cell adhesion molecule implicated in axon tract development. In this report, we show that DEGA/AMIGO-2 mRNA is differentially expressed in B45% of tumor versus normal tissue from gastric adenocarcinoma patients. Stable expression of a DEGA/AMIGO-2 antisense construct in the gastric adenocarcinoma cell line, AGS, led to altered morphology, increased ploidy, chromosomal instability, decreased cell adhesion/migration, and a nearly complete abrogation of tumorigenicity in nude mice. These findings suggest a potential etiologic role for DEGA/AMIGO-2 in gastric adenocarcinoma.
Introduction
Although less prominent in North America, neoplasia of the stomach is the second most common cancer worldwide and is associated with a 5 year survival rate of less than 20% (Chan et al., 1999) . Gastric adenocarcinoma accounts for 495% of these cases and the pathology differentiates the carcinoma into two distinct types: diffuse (proximal stomach) and intestinal (distal stomach) (Chan et al., 1999; Crookes, 2002) . In general, the cancer initially spreads locally within the gastric wall serosa and then metastasizes to lymph nodes via the peritoneal cavity. Complete surgical resection at early stages offers the best chance for a cure and emphasizes the need for early diagnosis and treatment. Aside from dietary and socioeconomic factors, Helicobacter pylori infection has recently emerged from epidemiological studies as a possible environmental etiologic factor (Danesh, 1999; Ebert et al., 2000; Konturek et al., 2001; Moayyedi and Ford, 2002) . With respect to molecular etiology, integrated research examining genetic and epigenetic events over the past 15 years has identified abnormalities in several genes at different stages and in different types of gastric cancer. However, the vast majority of these genes are also involved in other cancers and primarily encompass proto-oncogenes (eg K-sam (Sakamoto et al., 1986) , c-met (Kuniyasu et al., 1992 (Kuniyasu et al., , 1993 , HER-2/neu (Kono et al., 2000; Ross and McKenna, 2001) ), tumor suppressors (eg p53 (Hollstein et al., 1996) , APC (El-Rifai and Powell, 2002) ), cell cycle mediators (eg cyclin D1 (Arber et al., 1996) , cyclin E (Akama et al., 1995) ), and cell adhesion molecules (eg Ecadherin/b-catenin (Shun et al., 2001; Woo et al., 2001) , CD44 (Mayer et al., 1993; Yokozaki et al., 1994) ) (for a review of genes involved in gastric cancer, see Yasui et al., 2001; El-Rifai and Powell, 2002) . While characterization of these abnormalities has provided and should continue to provide further insight into the development and progression of gastric adenocarcinoma, efforts to identify new and more gastric adenocarcinoma-specific genes may be of greater importance to the understanding and possible diagnosis and/or treatment of stomach cancer.
Toward this end, we utilized a differential gene expression approach to search for genes involved in a variety of cancers and discovered DEGA, a novel gene encoding a cell surface protein differentially expressed in B45% of human gastric adenocarcinomas. Very recently, DEGA was found to be an exact match to AMIGO-2, a newly identified, but functionally uncharacterized cell adhesion molecule related to AMIGO, a leucine-rich repeat (LRR) superfamily member implicated in axon tract development (Kuja-Panula et al., 2003) . LRR motifs are generally comprised of 20-29 residues that harbor a conserved 11 residue consensus segment (LXXLXLXXLXL; X can be any amino acid and L can be a leucine, valine, isoleucine, or phenylalanine) (Iozzo, 1997; Hocking et al., 1998; Kobe and Kajava, 2001) . These motifs, which have been found repeated up to 38 times in a given protein, are believed to mediate protein-protein interactions and do not appear to be restricted to certain protein types or protein functions (Kobe and Deisenhofer, 1995; Kobe and Kajava, 2001 ). In fact, LRR superfamily members are extremely diverse with respect to their structure, localization, and function.
In this report, we have begun to characterize DEGA/ AMIGO-2 and discuss its involvement in human gastric adenocarcinoma.
Results
DEGA/AMIGO-2: cDNA cloning, sequence homology, and amino-acid analysis In a search for novel genes differentially expressed in a variety of cancers, we started with a murine hematopoietic stem cell subtractive cDNA library (Phillips et al., 2000) . Approximately 7500 ESTs from this library were placed on DNA microarrays and hybridized with cDNA prepared from a variety of murine cancer cell lines and corresponding normal tissue. One EST, S30-21616, was identified as being 7.6-fold differentially expressed in the murine renal cancer cell line, RAG, versus normal kidney tissue. This EST was sequenced and 522 bps were used to BLAST the NCBI nonredundant sequence databases. Although S30-21616 showed no homology to any full-length murine cDNA sequences, it showed B85% similarity to a portion of a human endometrial cancer partial cDNA clone (IMAGE:3625286) and to several human chromosome 12 BAC clones. Owing to the high homology observed between S30-21616 and IMAGE:3625286, it was likely that the latter represented the human homolog of S30-21616. This presumption was confirmed following murine-human chromosomal syntenic analysis using the Celera human and murine databases. The IMAGE:3625286 DNA sequence was also used as a template to generate PCR primers for RT-PCR of the DEGA ORF, 3 0 UTR UTR and 5 0 UTR from A549 cells (data not shown). When these PCR products were compiled, a final cDNA of 3769 bp was generated for DEGA (Figure 1a) that coincided with the approximately 2-3.5 kb transcript sizes observed in Northern blot analyses of A549 cells (data not shown) as well as in AGS and NCI-SNU-16 gastric adenocarcinoma cells (Figure 3c ). This range in transcript sizes was also observed in Genbank cDNAs expressed in testis, stomach, lung, and uterus, and are likely the result of alternative usage of multiple poly A signal sequences present in the 1732 bp 3 0 UTR of DEGA cDNA (see Figure 1a) . The ORF was determined to be 1569 bp in length and the sequence encoding the initiator methionine was flanked by sequence consistent with the Kozak consensus sequence (Kozak, 1987) . The DEGA gene product (Figure 1b) is predicted to encode a protein of 522 amino acids and is estimated to have a molecular mass of 57.9 kDa and a pI of 8.40. It possesses a signal sequence and a transmembrane domain suggesting that it may localize to the cell surface. Its putative extracellular portion contains an Ig domain and five leucine-rich repeats (LRRs) flanked by cysteine residues present in LRR-N-terminal (LRR-NT) and LRR-Cterminal (LRR-CT) domains. Consequently, DEGA appears to belong to the LRR superfamily. The putative cytosolic portion of DEGA contains 102 amino acids and lacks the presence of any known protein domains. However, approximately one-fifth or 20 of the cytosolic residues are either a serine or a threonine that may become phosphorylated and provide a docking site for intermediates of signaling pathways, thereby underscoring the possibility that DEGA may participate in signal transduction. When analysed by Scansite (Yaffe et al., 2001) , an algorithm to predict which amino acid could be phosphorylated and by what kinase, the following kinases were predicted to phosphorylate the DEGA cytosolic serine and threonine residues shown in parentheses: protein kinase C (T-428, S-499); GSK3 (S-442, S-504); ERK1 (S-446); casein kinase II (S-454, S-504); casein kinase I (S-504, S-511); protein kinase A (S-504); and AKT kinase (S-504, S-506, S-508) .
During the preparation of this manuscript, BLAST searches for sequence similarity to DEGA revealed an exact match to AMIGO-2, a recently identified, but functionally uncharacterized protein that is related to AMIGO, a LRR family member implicated in axon tract development (Kuja-Panula et al., 2003) . Consequently, we refer to DEGA as DEGA/AMIGO-2.
Subcellular localization of DEGA/AMIGO-2
Given that the DEGA/AMIGO-2 ORF revealed a signal peptide and transmembrane sequence, we hypothesized that the protein was expressed on the plasma membrane. To determine the subcellular localization of DEGA/ AMIGO-2, we engineered a fusion protein whereby enhanced green fluorescent protein (EGFP) was fused to the C-terminus of full-length DEGA/AMIGO-2. This was accomplished by cloning the DEGA/AMIGO-2 cDNA into pEGFP-N1 and stably transfecting 293 cells. The resulting cell lines showed definitive cell surface expression by fluorescence microscopy (Figure 2 ). To assess expression of DEGA/AMIGO-2 cDNA in human normal and tumor tissues, we used cancer profiling array (CPA) I and II (BD Biosciences Clontech) (Figure 3a and b) . CPA I and II contain pairs of cDNA generated from tumor and corresponding normal tissue samples derived from individual patients and spotted side-by-side on a nylon membrane. These arrays were probed with a C-terminal DEGA/ AMIGO-2 cDNA fragment encompassing nucleotides 1540-2045. With respect to differential expression in tumor versus normal samples, DEGA/AMIGO-2 was differentially expressed in 56% of thyroid (9/16; 5/6 in CPA I and 4/10 in CPA II), 57% of pancreatic (4/7 in CPA II), and 45% of stomach cancers (17/38; 14/28 in CPA I and 3/10 in CPA II). While not exhibiting a profile of significant differential tumor versus normal expression, significant absolute DEGA/AMIGO-2 expression levels were observed in some patient tumor cDNA isolates from breast (25%), uterus (28%), ovary Since B45% of the stomach cancer patient samples (gastric adenocarcinomas) immobilized on CPA I and II showed differential expression of DEGA/AMIGO-2 in their tumors and all of these patients expressed seemingly insignificant amounts of DEGA/AMIGO-2 in their adjacent normal stomach tissue, we were drawn to this patient set for the possibility that DEGA/ AMIGO-2 may play a pivotal role in the development or progression of at least a subfraction of gastric adenocarcinoma. To begin to characterize the role of DEGA/AMIGO-2 in gastric adenocarcinoma, Northern blot analysis was used to determine DEGA/AMIGO-2 expression levels in the following gastric adenocarcinoma cell lines: AGS, NCI-N87, RF-1, KATOIII, KKVR, NCI-SNU-16, and NCI-SNU-1 (Figure 3c ). AGS and NCI-SNU-16 cells were found to express DEGA/ AMIGO-2, with the former demonstrating B8-fold greater expression over the latter.
To determine expression of DEGA/AMIGO-2 in nongastric adenocarcinoma cell lines, we probed a cDNA dot blot prepared from a variety of cancer lines (Cancer Cell Line Profiling Array, BD Bioscience; Figure 3d ) with a DEGA/AMIGO-2 cDNA probe encompassing nucleotides 1204-1709 (numbering based on Figure 1a ). The highest expression observed was in lung NCI-H1299 and A549 cells; kidney ACHN cells; and U2-OS osteosarcoma cells. Lower, yet significant, expression was observed in the 786-O renal line, MDA-MB-231 breast cancer cells, and in the ovarian cancer line, SK-OV-3.
Stable expression of an antisense DEGA/AMIGO-2 construct in the gastric adenocarcinoma cell line, AGS, leads to altered morphology, increased ploidy, chromosomal instability, and abrogated tumorigenicity
The expression profile of DEGA/AMIGO-2 suggests that it may play a functional role in the development or progression of a subset of human gastric adenocarcinomas. To begin to address this notion, we stably expressed an antisense DEGA/AMIGO-2 construct or an empty vector construct in the human AGS cell line that was shown to express significant levels of DEGA/ AMIGO-2 mRNA. In this way, we could establish and compare these clones. To generate DEGA/AMIGO-2 antisense clones, a nucleotide fragment encompassing either the entire DEGA/AMIGO-2 ORF or the 5 0 most 608 nucleotides was cloned into pIRESPURO2 in reverse orientation and stably transfected into AGS cells. Concurrently, the empty pIRESPURO2 vector was also stably transfected into AGS cells. Northern blot analysis of DEGA/AMIGO-2 expression revealed several clones demonstrating significant and stable downregulation of DEGA/AMIGO-2 expression. Two clones -AGS DEGA/AMIGO-2 anti-sense clone #6 and #11 (five-and 14-fold reduction versus empty vector transfectants, respectively; see Figure 4a ) were selected for subsequent comparison with AGS empty vector clone #15. Several consequences of DEGA/AMIGO-2 downregulation were noted. Cells from the antisense clones were vacuolated and showed an approximate fivefold increase in size. Within the enlarged nucleus, condensed chromatin was clearly visible and the cells were reminiscent of cells in mitosis just prior to chromosomal alignment and segregation (Figure 4b, right panel) . After staining AGS DEGA/AMIGO-2 antisense and empty vector clones with propidium iodide, flow cytometry was used to compare their DNA content and therefore cell cycle profiles (Figure 4b, left panel) . AGS empty vector cells demonstrated a typical DNA content/cell cycle profile for proliferating cells, with a majority of cells in G 0 /G 1 (2n), followed in quantity by cells in G 2 /M (4n) and S phase. In contrast, AGS DEGA/AMIGO-2 antisense clones #6 and #11 displayed a dramatic alteration in this profile. Increased DNA content was clearly apparent with an abundance of cells exhibiting a 4n (G 2 /M) and 44n DNA content. A significant number of subG 0 /G 1 cells were not observed in the DNA content profile of either AGS empty vector or AGS DEGA/AMIGO-2 antisense clone #6 or #11 cells. As this can be an indicator of apoptotic cells, apoptosis was apparently not observed.
To independently confirm the increased DNA content, we performed chromosomal analysis of the AGS DEGA/AMIGO-2 antisense and empty vector clones (Table 1) . The average metaphase chromosome number for the AGS DEGA/AMIGO-2 antisense and empty vector transfected clones were 91-97 versus 49, respectively. When the metaphase spreads were examined for 2n, 4n, and 44n DNA content (Table 1) , those of the AGS DEGA/AMIGO-2 antisense clones #6 and #11 were significantly skewed to a 4n and 44n DNA content. Few were 2n; especially for antisense clone #11. In contrast, the majority of metaphases analysed for the AGS empty vector clone #15 exhibited a 2n content and none were 44n. Karyotype analysis also revealed that downregulation of DEGA/AMIGO-2 in AGS resulted in additional chromosomal aberrations not seen in the AGS empty vector clone (Table 2) . For example, both antisense clones possessed additional copies of chromosomes X, 14, and 18.
Since AGS cells are tumorigenic in nude mice, we decided to explore whether suppression of DEGA/ AMIGO-2 expression in these cells could negatively influence their tumorigenic potential. To accomplish this task, we subcutaneously injected nude mice with AGS empty vector clones or AGS DEGA/AMIGO-2 antisense clones #6 and #11 and monitored tumor volume (mm 3 ) on a weekly basis in three separate experiments ( Figure 5 ). After 75 days, 12/12 and 19/19 mice, respectively, injected with AGS and AGS empty vector clone #15 cells developed tumors with a mean tumor volume of nearly 800 mm 3 . In sharp contrast, only 6/12 mice injected with AGS DEGA/AMIGO-2 antisense clone #6 and 6/19 mice injected with AGS DEGA/ AMIGO-2 antisense clone #11 developed tumors with a mean tumor volume of only 20 mm 3 . These differences in tumor formation were statistically significant (P ¼ 0.0052). (6) To compare the cell adhesive and migratory abilities of AGS DEGA/AMIGO-2 antisense clone #11 and empty vector-transfected cells, we utilized porous membrane cell culture inserts. This assay was performed by seeding cells into the upper chamber of the insert and allowing them to pass through the porous membrane to adhere to and migrate through the collagen-coated underside in response to fetal bovine serum (FBS). Figure 6b shows a representative experiment (n ¼ 2) where migrated cells were visualized on the underside of the collagen-coated membrane following exposure to 10% FBS or serumfree media. In comparison to AGS empty vectortransfected cells, AGS DEGA/AMIGO-2 antisense clone #11 cells revealed a nearly complete abolition of collagen adhesion/migration in response to 10% FBS. To ensure that the lack of increase in migrated DEGA/ AMIGO-2 antisense clone #11 cells was not due to their inability to seed the upper chamber of the cell culture insert or their ability to pass entirely through the collagen-coated membrane to the media in the lower chamber, cell counts were, respectively, taken from the upper chamber after seeding under serum-free conditions and in the lower chamber following completion of the experiment. No difference in cell count was observed in either chamber between the AGS DEGA/AMIGO-2 antisense and empty vector clones.
Discussion
Following a search for genes involved in cancer, we identified DEGA, a novel gene differentially expressed in B45% of human gastric adenocarcinoma tumor samples. Sequence analysis of the extracellular region of the DEGA protein revealed an IgG domain and five LRR motifs typically found in LRR-containing proteins present on the cell surface (Kobe and Deisenhofer, 1994 Deisenhofer, , 1995 . Since LRR motifs are believed to mediate protein-protein interactions, their presence in DEGA and other cell surface LRR proteins implied a possible role in cell adhesion or ligand binding. This notion is consistent with the functions of many LRR family members expressed on the cell surface. For example, the trk receptor contains several LRRs that have been implicated in binding to its ligand, nerve growth factor and LRR motifs are also believed to mediate platelet adhesion by platelet glycoprotein Iba and V (Kobe and Deisenhofer, 1994 Deisenhofer, , 1995 . Analysis of the cytosolic region of the DEGA gene product revealed no known protein domains. However, 20 of the 102 cytosolic amino acids were either a serine or a threonine, suggesting a possible role for DEGA in signal transduction. This notion was further supported when the Scansite phosphorylation prediction algorithm (Yaffe et al., 2001 ) predicted seven of the 20 cytosolic serines and threonines to be phosphorylated by either casein kinase I and II, protein kinase A and C, as well as the GSK3, ERK1, and AKT kinases.
At the time of discovery and characterization, BLAST searches did not reveal exact matches to the novel fulllength DEGA cDNA or protein sequences. While this manuscript was in preparation, however, a repeat BLAST search uncovered an exact match to AMIGO-2, a newly identified but functionally uncharacterized protein related to AMIGO, a LRR family member implicated in axon tract development (Kuja-Panula et al., 2003) . Through the use of coimmunoprecipitation and purified protein/bead aggregation assays, KujaPanula et al. demonstrated that AMIGO-2 could participate in homophilic and heterophilic interactions with AMIGO family members (i.e. AMIGO and AMIGO-3). This finding, coupled with sequence analyses and our cell localization and adhesive/migratory data, suggest that DEGA/AMIGO-2 belongs to the functionally diverse LRR superfamily and that it may function as a cell adhesion molecule involved in signal transduction.
Our studies of DEGA/AMIGO-2 expression focused on several tumor and normal tissues. With respect to the latter, we demonstrated DEGA/AMIGO-2 expression in lung, colon, and rectum, but the strongest expression observed was in breast, ovary, uterus, and cervix, suggesting a possible role for DEGA/AMIGO-2 in female reproductive tissues. Since we were primarily interested in cancer genes that were differentially expressed in tumor versus normal tissue, we used cancer profiling cDNA arrays, to assess the differential expression of DEGA/AMIGO-2 in 18 human cancers. With the exception of thyroid and pancreatic cancer, only Figure 5 Tumorigenicity of AGS clones stably transfected with an antisense DEGA/AMIGO-2 construct or an empty vector. Ten million AGS empty vector clone #15 and antisense DEGA/ AMIGO-2 clones #6 and #11 were mixed with Matrigel and subcutaneously injected in athymic (nu/nu) mice. Untransfected AGS cells (AGS WT) were also included as a positive control. Tumor volumes were measured weekly using calipers. Three independent experiments were conducted and the number of tumor-bearing mice versus the total number of mice injected were as follows: AGS WT (12/12); AGS empty vector clone #15 (19/19); AGS DEGA/AMIGO-2 antisense clone #6 (6/12); and AGS DEGA-AMIGO-2 antisense clone #11 (6/19). Tumor volume differences between the AGS DEGA/AMIGO-2 antisense clones and the AGS WT and empty vector-transfected cells were statistically significant (P ¼ 0.0052) DEGA/AMIGO-2 involvement in gastric adenocarcinoma KE Rabenau et al gastric adenocarcinoma exhibited increased expression of DEGA/AMIGO-2 in approximately 45% of tumor versus normal patient tissue samples. Initially, we were surprised that DEGA/AMIGO-2 was differentially expressed in tumors from only three cancers and not in tumors from all cancers, especially given the importance we later demonstrated for DEGA/AMI-GO-2 expression in gastric adenocarcinoma. We came to realize, however, that this expression trend was not necessarily uncommon for tumor-related genes. Our inhouse experiences using Becton Dickinson's cDNA cancer profiling arrays with a variety of novel and known (well validated) tumor-related genes also demonstrated DEGA/AMIGO-2-like expression profiles. For example, when the well-validated cancer target, EGFR, was analysed (data not shown), it clearly showed differential expression in nearly all normal versus tumor breast tissue from breast cancer patients while exhibiting differential expression in tumor tissue derived from several lung and kidney cancer patients (therapeutic indications for current anti-EGFR therapies). Moreover, although EGFR was also expressed highly in some tumors from colon cancer patients on the cDNA cancer profiling array, it was not differentially expressed in tumor versus normal colon tissue from these same patients. Aside from DEGA/AMIGO-2's differential tumor expression profiles in gastric, thyroid, and pancreatic tumors, we also observed significant absolute expression levels in a subset of patient samples and cell lines representing a variety of other cancers. Thus, the possibility that DEGA/AMIGO-2 may play a role in a subset of these cancers awaits further investigation. To determine whether DEGA/AMIGO-2 expression was required for the proliferation/tumorigenicity of gastric adenocarcinoma, we employed a conventional antisense approach to stably repress DEGA/AMIGO-2 While several AGS clones were generated with stably repressed levels of DEGA/AMIGO-2 expression, two were used to compare to AGS empty vector clones. Whiles several consequences of DEGA/AMIGO-2 downregulation were noted in these two clones, it is important to note that these consequences were not restricted to these clones, but were apparent in all antisense clones showing at least fivefold repression of DEGA/AMIGO-2 expression levels (data not shown). Consequently, the phenotypes observed for the AGS DEGA/AMIGO-2 clones were specifically due to downregulation of DEGA/AMIGO-2 expression and not the result of clonal heterogeneity.
To summarize, the consequences of DEGA/AMIGO-2 downregulation in AGS cells were: altered morphology, increased cell size and DNA content (ploidy), chromosomal instability and nearly complete inhibition of tumorigenicity, and cell adhesion to and migration through collagen. Initially, we were surprised to observe that downregulation of the expression of a single gene, namely DEGA/AMIGO-2, could lead to an increase in DNA content and chromosomal instability. However, this observation is not unique to DEGA/AMIGO-2. Antisense inhibition of BUB1 results in a similar phenotype in normal human fibroblasts (Musio et al., 2003) . In addition, overexpression of the human Ha-ras oncogene increases ploidy and genomic instability in murine fibroblasts within one cell cycle (Denko et al., 1994) . While repressed expression of BUB1 leading to chromosomal instability is perhaps logically expected, chromosomal instability as a result of overexpression of Ha-ras is not obvious due to its proximity to the plasma membrane and to a lack of evidence suggesting that Haras acts directly upon the cell's chromosomes. Similarly, it is not obvious, yet intriguing that DEGA/AMIGO-2, a putative cell adhesion molecule, leads to chromosomal instability upon loss of its expression. While Denko et al. do not know the mechanism by which overexpression of Ha-ras leads to chromosomal instability, they did propose hypotheses that accommodated their data and which we feel also accommodate our data involving repression of DEGA/AMIGO-2. One hypothesis is centered on that fact that Ha-ras is known to affect multiple cellular pathways that could impinge upon the integrity of chromosomal DNA. This could also apply to repression of DEGA/AMIGO-2 and its currently unidentified pathways. Next, they postulate that signal transduction by overexpressed Ha-ras may induce a nucleolytic activity that saturates the DNA repair capacity. In the case of DEGA/AMIGO-2, repression of its expression/signaling could also have the same effect. These hypotheses await further experimentation.
When tested for their ability to form tumors in athymic (nu/nu) mice, the two independently generated AGS DEGA/AMIGO-2 antisense clones exhibited a dramatic inhibition in comparison to the empty vector clone (mean tumor volumes of B20 and B800 mm 3 , respectively). Although this finding suggested a direct role for DEGA/AMIGO-2 in the maintenance of the tumorigenic state of AGS cells, it did not account for the lack of difference we observed in in vitro proliferative potential between the AGS DEGA/AMIGO-2 antisense and empty vector clones. We put forth two possible explanations for this discrepancy. Since data presented in this report and data from Kuja-Panula et al. (2003) demonstrate that DEGA/AMIGO-2 may function as a putative signaling cell adhesion molecule, we propose that DEGA/AMIGO-2 may be required for tumor attachment. Consequently, downregulation of its expression would negatively impact the tumorigenicity of AGS cells. Precedence for this hypothesis stems from antisense expression of laminin-binding protein, which causes significant inhibition of attachment and invasion in a human colon carcinoma cell line (Mafune and Ravikumar, 1992) . Other cell adhesion molecules involved in stomach cancer include CD44 (Mayer et al., 1993; Yokozaki et al., 1994 ) and Ecadherin/b-catenin (Shun et al., 2001; Woo et al., 2001) . Interestingly, since the loss of E-cadherin expression appears to correlate with gastric cancer progression, we hypothesize that it may be lost in gastric cancer to allow for metastasis, while expression of DEGA/AMIGO-2 may be required as an attachment factor for tumorigenesis and possibly metastasis. Chromosomal instability may be an alternative explanation for the inability of AGS DEGA/AMIGO-2 antisense clones to form tumors. It is possible that the additional chromosomal aberrations, which arose due to chromosomal instability observed in the AGS DEGA/AMIGO-2 antisense clones, negatively affected a variety of genes required for the tumorigenicity of AGS cells. For example, additional copies of the X chromosome and chromosome 18 that carry the ING and DCC tumor suppressors, respectively, could explain the inability of AGS DEGA/AMIGO-2 antisense clones to form tumors in vivo. The view that chromosomal instability may not always be the driving force in tumorigenesis, and in fact, that it may be detrimental, is not unprecedented and has been supported by several investigations of colorectal cancer (Cahill et al., 1999; Tomlinson and Bodmer, 1999; Nowak et al., 2002; Sieber et al., 2003) . Whether the difference in the in vitro and in vivo proliferation potentials of the AGS DEGA/ AMIGO-2 antisense clones is attributable to cell adhesion and/or chromosomal instability/aberrations, it is important to emphasis that these mechanisms may be mutually exclusive.
In summary, through the discovery of DEGA/ AMIGO-2, we have identified a novel factor that may function not only as a signaling cell adhesion molecule, but that may be required for the tumorigenesis of a subset of human gastric adenocarcinomas. Through our antisense studies using a gastric adenocarcinoma cell line, we have shown that the inhibition of DEGA/ AMIGO-2 expression negatively impacts tumor growth as well as altering chromosomal ploidy and stability. Detailed genetic, molecular, and biological characterization of DEGA/AMIGO-2 is now required to determine its requirement and precise function/mechanism in gastric adenocarcinoma and possibly other cancers. Finally, it will be of interest to determine whether DEGA/AMIGO-2 will serve as a diagnostic and/or prognostic tool for neoplasia of the stomach.
Materials and methods

Cell culture
Cell lines used in this study were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) and media used for their propagation was purchased from Gibco, Grand Island, NY, USA. Cell lines and their respective growth media (shown in parentheses) were as follows: AGS (F-12), 293 (Dulbecco's modified Eagle's medium (DMEM)), KKVR (Iscove's DMEM), RF-1 (Leibovitz's L-15), and NCI-SNU-1, NCI-SNU-16, NCI-N87, KatoIII (RPMI). All media were supplemented with 2 mM L-Glutamine (Gibco, Grand Island, NY, USA) and 10% FBS(Hyclone, Logan, UT, USA). KatoIII and KKVR, however, were grown in 20% FBS and NCI-N87 and KKVR growth media were additionally supplemented with 1.5 g/l sodium bicarbonate.
DEGA/AMIGO-2 cDNA cloning
RT-PCR was performed to amplify the DEGA/AMIGO-2 ORF from Marathon-Ready A549 and spleen cDNA preparations (BD Biosciences Clontech, Palo Alto, CA, USA) using the following forward (5 0 -ATG TCG TTA CGT GTA CAC ACT CTG-3 0 ) and reverse primers (5 0 -TTA AGT GGA CGC CAC AAA AGG TGT G-3 0 ) (Bio-Synthesis Incorporated, Lewisville, TX, USA); start and stop codons are underlined. Titanium Taq polymerase (BD Biosciences Clontech, Palo Alto, CA, USA) was utilized with RT-PCR conditions described in the Marathon-Ready cDNA manual: 941C, 30 s; 681C, 2 min. The DEGA/AMIGO-2 ORF PCR product (1569 bp) was cloned into pCR2.1 (Invitrogen Corporation TA Cloning Kit, Carlsbad, CA, USA) and sequence verified (Molecular Genetics Instrumentation Facility, University of Georgia, Athens, GA; GENEWIZ Inc., North Brunswick, NJ, USA). To obtain DNA sequence upstream of the DEGA/AMIGO-2 start codon, 5 0 RACE was performed using A549 Marathon Ready cDNA as explained above with few modifications. AP1, a forward primer (included with the Marathon Ready cDNA) and a DEGA/AMIGO-2 gene-specific reverse primer (5 0 -AAC TCA GGT CCA GTC TCT TAA TCA G-3 0 ) produced a PCR product after 35 rounds of amplification (941C, 30 s; 571C, 30 s; 681C, 2 min.) that was subcloned into pCR2.1 and sequence verified. Sequence representing the 3 0 UTR of DEGA/AMI-GO-2 was initially obtained computationally from the human chromosome 12 BAC clone, GS1-99H8 (Genbank accession #AC004010). A series of PCR primers were subsequently designed to determine the longest 3 0 UTR sequence present in the A549 cDNA preparation. A PCR product generated by the following primer set: forward primer 5 0 -ATG TCG TTA CGT GTA CAC ACT CTG-3 0 (start codon underlined) and reverse primer 5 0 -TGG ACC TCC AAT CTT CAC CAG G-3 0 , which initiates at nucleotides 3564-3585 of the DEGA/AMIGO-2 ORF (Figure 1a) , identified the longest 3 0 UTR segment.
Bioinformatics
To confirm that the S30-21616 EST represented a portion of the murine homolog of the human DEGA/AMIGO-2 partial cDNA IMAGE:3625286 clone, murine-human chromosomal syntenic analysis was performed with access to the Celera human and murine genomic databases. To determine whether DEGA/AMIGO-2 cDNA and amino-acid sequences were similar to sequences present in the public domain, BLAST searches were performed using the National Center for Biotechnology Information website (http://www.ncbi.nlm. nih.gov). Sequence representing the 3 0 UTR of the DEGA/ AMIGO-2 gene was obtained computationally from human chromosome 12 BAC clone, GS1-99H8 (Genbank accession #AC004010) and scanned for polyadenylation sites using polyadq software (http://argon.cshl.org/tabaska/polyadq_ form.html). Prediction of protein motifs and domains as well as glycosylation and phosphorylation sites present in the DEGA/AMIGO-2 gene product were accomplished using prediction servers at the Center for Biological Sequence Analysis (http://www.cbs.dtu.dk/services), the Simple Modular Architecture Research Tool (SMART) V3.5 (http://smart.embl-heidelberg.de/) and Scansite (http://scansi te.mit.edu).
Stable expression of a DEGA/AMIGO-2-EGFP fusion construct and a DEGA/AMIGO-2 antisense construct in 293 and AGS cells, respectively
To determine the subcellular localization of DEGA/AMIGO-2, we engineered a fusion protein whereby an EGFP was fused to its C-terminus. This was accomplished by PCR amplifying the DEGA/AMIGO-2 ORF and cloning it into XhoI/AgeI sites of pEGFP-N1 (BD Biosciences Clontech, Palo Alto, CA, USA). This PCR reaction was performed as described in the DEGA/AMIGO-2 cDNA cloning section with the exception that the forward primer used (5 0 ATC CTC GAG GCG ACC ATA ATG TCG TTA CGT GTA CAC ACT 3 0 ) contained the native Kozak sequence and a XhoI site (underlined) 5 0 to the start codon shown in bold. The reverse primer used (5 0 GAT CAC CGG TGC AGT GGA CGC CAC AAA AGG TGT GTC 3 0 ) contained an AgeI site (underlined) 3 0 of the stop codon shown in bold. The DEGA/AMIGO-2-EGFP construct was stably transfected into 293 and AGS cells using FUGENE6 transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN, USA) as outlined by the manufacturer. A 2 : 1 and 3 : 1 FUGENE6:DNA ratio was used, respectively. Transfected 293 cells were left for 2 days at 371C after which time they were plated in limiting dilution and subjected to selection with 800 mg/ml Geneticin (Sigma-Aldrich Corp., St Louis, MO, USA), respectively. Individual clones were isolated by trypsinization using cloning rings and allowed to expand. To determine the subcellular localization of the DEGA/ AMIGO-2-EGFP fusion protein, clones were assessed using a Zeiss Axioskop fluorescent microscope.
To generate DEGA/AMIGO-2 antisense clones, a nucleotide fragment encompassing the entire ORF of DEGA/ AMIGO-2 as well as one that comprised the 5 0 most 608 nucleotides of its ORF (generated from a partial EcoRI digest of pCR2.1-DEGA/AMIGO-2) were cloned into pIRE-SPURO2 (BD Biosciences Clontech, Palo Alto, CA, USA) in reverse orientation and stably transfected into AGS cells. Concurrently, pIRESPURO2 was also stably transfected into these cells to serve as an empty vector control. Transfection and clone isolation was performed exactly as described for the DEGA/AMIGO-2-EGFP fusion with the exception that cells were selected with 0.4 mg/ml puromycin (Sigma-Aldrich Corp., St Louis, MO, USA).
cDNA dot blot analysis of DEGA/AMIGO-2 expression in cancer patient samples
To determine expression of DEGA/AMIGO-2 in a variety of tumor and normal tissues, CPA I and II (BD Biosciences Clontech, Palo Alto, CA, USA) were probed with a cDNA fragment encompassing ORF nucleotides 1540-2045 (numbering based on Figure 1 ) as per the manufacturer's recommendations. The probe was labeled with [a-32 P]dCTP (Perkin-Elmer Life Sciences, Inc., Boston, MA, USA) and isolated using the Prime-It II kit (Stratagene Cloning Systems, La Jolla, CA, USA). CPA I and II are nylon arrays containing normalized cDNA from 241 and 160 tumor and corresponding normal tissues obtained from individual cancer patients, respectively. Tissues represented by CPA I include breast, uterus, colon, stomach, ovary, lung, kidney, rectum, thyroid, cervix, small intestine, pancreas, and prostate. In addition to these tissues, CPA II carries bladder, testis, and skin tissue. These arrays also contain positive and negative controls as well as cDNA isolated from nine cancer cell lines: HeLa, Daudi, K-562, HL-60, G-361, A549, Molt-4, SW480, and Raji. For more information regarding CPA I and II, see the following website: http://bioinfo.clontech.com/ darray.
To determine DEGA/AMIGO-2 expression in nongastric adenocarcinoma cell lines, the DEGA/AMIGO-2 probe and conditions used for CPA I and II were also used to hybridize BD Bioscience's Cancer Cell Line Profiling Array, which contains cDNA from cell lines representing cancer of the lung 
Northern blot analysis
To determine expression of DEGA/AMIGO-2 in gastric adenocarcinoma cell lines and in AGS DEGA/AMIGO-2 antisense and empty vector clones, standard Northern blotting procedures were followed. Total RNA was isolated using the Micro-to-Midi Total RNA system (Invitrogen Corporation, Carlsbad, CA, USA) exactly as recommended by the manufacturer and 5 mg was resolved on a 1.2% denaturing formaldehyde gel and transferred to Nytran SuPerCharge membranes (Schleicher & Schuell, Inc., Keene, NH, USA). Blots were hybridized with the 32 P random-labeled DEGA/AMIGO-2 C-terminal probe used to probe the CPA I and II cDNA blots. Hybridizations were performed for 1 h at 681C using ExpressHyb solution (BD Biosciences Clontech, Palo Alto, CA, USA). Three 10 min room temperature washes (2 Â SSC, 0.05% SDS) and two 20 min 501C washes (0.1 Â SSC, 0.1% SDS) followed. Membranes were rinsed in 2 Â SSC and exposed overnight at À701C to Kodak Biomax MR film (Eastman Kodak Company, Rochester, NY, USA).
Wright-Giemsa staining
To differentiate nuclear and cytoplasmic morphology of AGS DEGA/AMIGO-2 antisense clones, Giemsa staining was performed. Cells were grown to subconfluency on Lab-Tek II chamber slides (Nalgene Nunc International, Aurora, IL, USA) and stained with Wright-Giemsa stain according to the manufacturer's instructions (Thermo Shandon, Pittsburgh, PA, USA).
DNA content analysis
To measure DNA content, and therefore cell cycle profile, flow cytometry was utilized. AGS empty vector and DEGA/ AMIGO-2 antisense clones were grown in growth media, trypsinized, washed once in PBS and stained for 10 min at room temperature in the dark with the propidium iodide solution provided in the DNA QC Particles kit (Becton Dickinson). Cells were subsequently analysed on a Becton Dickinson FACSVantage flow cytometer using parameters outlined in the DNA QC particles kit.
Chromosome analysis
AGS empty vector #15 and DEGA/AMIGO-2 antisense clones were grown in culture as described above. Following conventional methods, chromosome preparations were generated from logarithmically growing cells following exposure to colcemid for 2 h. Chromosomes were trypsin-Giemsa banded and approximately 70-110 metaphases were analysed per cell line. Chromosome abnormalities were described using standard ISCN nomenclature.
Cell adhesion/migration assay
To compare the ability of AGS DEGA/AMIGO-2 antisense and empty vector-transfected clones to adhere to and migrate through collagen, cell culture inserts containing porous translucent polyethylene terephthalate track-etched membranes (8.0 mm pore size; Becton Dickinson Falcon) were utilized. Just prior to the assay, the underside of the porous membranes in the cell culture inserts were coated with collagen by aseptically removing the inserts from the packaging with sterile forceps and gently placing them into a 24-well Falcon plate filled with 700 ml of Vitrogen-100-purified collagen solution (25 mg/ml; Cohesion; Palo Alto, CA, USA). The inserts were left for at least 1 h at 41C and placed in a new 24-well plate containing either 700 ml serum-free media or 10% FBS. Next, 6 Â 10 5 viable cells that had been serum starved for 24 h were rinsed twice with PBS and seeded into the upper chamber of the cell culture insert in 300 ml serum-free media. Cells were then incubated another 24 h at 371C to allow for adhesion to and migration through the collagen-coated porous membrane on the underside of the cell culture insert. At the conclusion of the assay, media was aspirated from the inserts and washed twice with PBS. Nonmigrated cells on the upperside of the cell culture insert were removed with a Q-tip (dipped in PBS). The collagen-coated underside of the membrane containing the migrated cells was washed twice with PBS and fixed with buffered neutral formalin (10%; VWR; West Chester, PA, USA) for 10 min at RT. Following two washes with PBS, the migrated cells were permeabilized with PBS/0.1% Tween-20 for 5 min at RT and their nuclei stained with 700 ml Harris Modified Hematoxylin with Acetic Acid solution (Fisher Scientific; Fairlawn, NJ, USA) for 10 min at RT. Their cytoplasms were stained with Eosin-Y Alcoholic (Richard-Allan Scientific; Kalamazoo, MI, USA) for 2 min at RT. The cell culture inserts were then allowed to air dry upside down for 15 min at RT and the porous membranes removed from the cell culture inserts with a razor blade for transfer to a glass slide. Once mounted and cover-slipped, migrated cells on the underside of the collagen-coated membrane were visualized using bright field microscopy at Â 100 magnification.
Tumorigenicity analysis
AGS clones were suspended in serum-free growth media, placed on ice and thoroughly mixed with Matrigel (Collaborative Research Biochemicals, Bedford, MA, USA) at a 1 : 1 (v/v) ratio. Matrigel is derived from the Engelbroth-Holm-Swarm mouse sarcoma, which has been found to be a rich source of the ECM proteins: laminin, collagen IV, nidogen/enactin, and proteoglycan (Kleinman et al., 1982) . When mixed with cell lines, Matrigel enhances tumorigenesis (Terranova et al., 1986) . For each 1-2-month old, gender-independent athymic (nu/nu) mouse (Charles River Laboratories, Wilmington, MA, USA), ten million cells were injected in the flank subcutaneously and tumor volumes (mm 3 ) measured weekly using calipers for 11 weeks.
